ASCIA News

  • ASCIA Food Allergy e-training
    ASCIA Food Allergy e-training for Health Professionals has been substantially updated and the new course is available from 30 November 2021. First developed in 2011, the latest version is for suitable for medical practitioners, nurses and dietitians. The following six...
  • New ASCIA Chronic Rhinosinusitis Position Paper
    Chronic Rhinosinusitis (CRS) is one of the most common chronic conditions worldwide, with a significant health-economic impact.  CRS is generally subclassified into two dominant subgroups: CRS with Nasal Polyps (CRSwNP), and RS sine (without) NP (CRSsNP). CRS with Nasal Polyps...
  • Parliamentary Inquiry Report
    The Standing Committee on Health, Aged Care and Sport has tabled its report ‘The New Frontier: Delivering better health to all Australians’, following the Parliamentary Inquiry into approval processes for new drugs and novel medical technologies in Australia.  The three...
  • New Anaphylaxis Clinical Care Standard
    New standard of care to manage anaphylaxis will save lives A new Acute Anaphylaxis Clinical Care Standard has been developed by the Australian Commission on Safety and Quality in Health Care, in consultation with consumers and healthcare professionals, and is now available...
  • COVID-19 Vaccination Update
    COVID-19 vaccination is an important way to reduce the risk of developing COVID-19, which is caused by infection with the SARS-CoV-2 coronavirus. Even if a person does get infected, it is likely to be a milder illness if they have been vaccinated. Once there is a very high...
  • TGA approval for Pfizer COVID-19 vaccine booster dose in Australia
    The Therapeutic Goods Administration (TGA) has approved a booster dose of the Pfizer COVID-19 vaccine for individuals 18 years and older in Australia. The TGA approval means that the Pfizer COVID-19 vaccine has been found safe and effective to boost protection for...
  • National Allergy Strategy Updates
    The National Allergy Strategy is a partnership between ASCIA and Allergy & Anaphylaxis Australia. Several new and updated National Allergy Strategy resources have recently been launched, which are listed below.  NEW Allergy Aware Resource hub This resource hub contains the new...
  • Third COVID-19 vaccine dose recommended for people who are severely immunocompromised
    The Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement, prepared in consultation with ASCIA, which recommends a third primary dose of COVID-19 vaccine for people who are severely immunocompromised. This includes people with primary...
ASCIA Member Login

Site last updated: 24 Nov 2021
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...

Join our mailing list here...

AIFA: Donate Now
AIFA: Donate Now
National Allergy Strategy
National Allergy Strategy
ASCIA: WAO Member
ASCIA: WAO Member
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.